Iovance Biotherapeutics is the first mover in TIL therapy, as Amtagvi is the first and only FDA-approved tumor-infiltrating lymphocyte therapy for solid tumors and no rival is close to market. 2025 revenue jumped over 60% to $264M as it commercializes and scales. Its pipeline is expanding beyond melanoma into lung and cervical cancer and sarcomas, where early data showed a 50% response rate. H.C. Wainwright kept a Buy rating and $9 target, about 2.8x the ~$3.41 price. x.com 

Any Iovance buyout would have been in the works for at least six months, from a much lower valuation. Do not get greedy about its potential deal price now. x.com